Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, reflecting a nuanced shift in its technical outlook despite persistent valuation and fundamental challenges. The upgrade is primarily driven by improved technical indicators, while valuation metrics have become more expensive and financial trends remain flat, prompting a cautious stance for investors.

Bafna Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 24 April 2026, reflecting deteriorating technical indicators and an expensive valuation profile despite its strong long-term returns. The micro-cap pharmaceutical company faces challenges across quality, valuation, financial trends, and technical parameters, prompting a reassessment of its investment appeal.

Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting a reassessment of its price attractiveness amid evolving market dynamics and peer comparisons within the Pharmaceuticals & Biotechnology sector.

At Rs 138.73, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.87% on 23 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 139.45, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 5.0% on 16 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Bafna Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 16 Apr 2026, reflecting a nuanced improvement across technical indicators and valuation metrics despite ongoing challenges in financial performance. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, signalling a cautious but more favourable outlook amid mixed signals from quality and financial trends.

Bafna Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change, coupled with a downgrade in its overall Mojo Grade from Strong Sell to Sell, invites a closer examination of the company’s price attractiveness relative to its historical metrics and peer group benchmarks.

At Rs 133.87, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5.0% on 13 Apr 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance in supply and demand.

Bafna Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from fair to expensive territory, despite delivering mixed returns relative to the broader market. The micro-cap pharmaceutical player’s price-to-earnings (P/E) ratio now stands at 27.4, surpassing many peers, while its price-to-book value (P/BV) has risen to 3.7, signalling a premium that investors should carefully assess amid the company’s middling profitability metrics and sector dynamics.

At Rs 136.13, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 10% on 09 Apr 2026, with buyers queuing and no sellers willing to part with shares.

Bafna Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 March 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 07 April 2026, providing investors with the latest insights into the company’s performance and outlook.

At Rs 114.80, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bafna Pharmaceuticals Ltd locked at its upper circuit of 4.99% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.

At Rs 108.42, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 4.99% on 30 Mar 2026, with unfilled sell orders and a frozen price, reflecting a day where supply overwhelmed demand to the point the exchange intervened.

At Rs 111.84, sellers were still queuing — but there were no buyers willing to take the other side. Bafna Pharmaceuticals Ltd locked at its lower circuit of 5% on 27 Mar 2026, with unfilled sell orders and a frozen price.

Bafna Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 13 March 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 March 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.